Pralsetinib (Gavreto)

Mechanism of action

From the [NCI Drug Dictionary]: An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, BLU-667 binds to and targets various RET mutants and RET-containing fusion product.

Diseases for which it is used

• RET-positive NSCLC

History of changes in FDA indication

• 9/4/2020: Granted accelerated approval for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC)

Also known as

• Code name: BLU-667
• Brand name: Gavreto